Running Point Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Running Point Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$159K	–	149
2022 Q4	$159K	Hold	10,000	–	–	0.1%	114
2022 Q3	$164K	Hold	10,000	–	–	0.11%	99
2022 Q2	$141K	Hold	10,000	–	–	0.09%	104
2022 Q1	$242K	Buy	+10,000	New	+$242K	0.14%	83

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Running Point Capital Advisors's ACAD Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 10,000 shares — an estimated $159K sold.

Running Point Capital Advisors first reported a position in ACAD in Q1 2022 and held it in 4 quarters. The position peaked at $242K in Q1 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

Running Point Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 Acadia Pharmaceuticals shares in Q1 2023, an estimated $159K.
Running Point Capital Advisors first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Running Point Capital Advisors's Acadia Pharmaceuticals position peaked at $242K in Q1 2022.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.